Bausch Health Companies Inc. (BHC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bausch Health Companies Inc. (BHC) Healthcare & Pipeline Overview

Bausch Health Companies Inc. operates in the healthcare sector, focusing on pharmaceuticals, medical devices, and OTC products across eye health, gastroenterology, and dermatology. With a diverse portfolio and five operating segments, Bausch Health serves global markets, facing competition from both generic and branded product manufacturers.

What Is the Investment Thesis for BHC?

Bausch Health Companies Inc. presents a complex investment case. With a market capitalization of $2.27B and a negative profit margin of -11.3%, the company's financial performance requires careful consideration. Key value drivers include the Bausch + Lomb segment, which focuses on vision care and surgical products, and the Salix segment, specializing in gastroenterology products in the U.S. Upcoming catalysts include potential regulatory approvals for new pharmaceutical products and expansion into emerging markets. However, investors must also consider risks such as ongoing litigation, debt management, and competition from generic drug manufacturers. The company's beta of 0.40 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

BHC Key Highlights

Market Cap: $2.27B, reflecting its current valuation in the market.

• Profit Margin: -11.3%, indicating challenges in profitability.
• Gross Margin: 61.7%, showcasing the potential for profitability before operating expenses.
• Beta: 0.40, suggesting lower volatility compared to the overall market.
• Dividend Yield: None, as the company does not currently offer a dividend.

Who Are BHC's Competitors?

BHC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BHC's Key Strengths?

Diverse product portfolio across multiple therapeutic areas.

• Global presence with operations in various countries.
• Established brands with strong market recognition.
• Focus on research and development.

What Are BHC's Weaknesses?

Negative profit margin.

• High debt levels.
• Exposure to generic competition.
• Dependence on key products.

What Could Drive BHC Stock Higher?

Potential regulatory approvals for new pharmaceutical products in key markets.

• Expansion of the Bausch + Lomb segment through strategic partnerships.
• Debt reduction initiatives to improve financial stability.

What Are the Key Risks for BHC?

Financial-distress signal — its Altman Z-Score of 0.09 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Product liability litigation and associated costs.
• Increasing competition from generic drug manufacturers.
• Economic downturns affecting consumer spending on healthcare products.
• Stringent regulatory requirements and compliance costs.

What Are the Growth Opportunities for BHC?

• Expansion in Emerging Markets: Bausch Health has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid economic growth and increasing healthcare spending, creating a strong demand for pharmaceutical and medical device products. By tailoring its product offerings to meet the specific needs of these markets and establishing strategic partnerships, Bausch Health can drive revenue growth. The global emerging markets pharmaceutical market is projected to reach $500 billion by 2028.
• New Product Development and Innovation: Investing in research and development to create innovative products is crucial for Bausch Health's long-term growth. Focusing on unmet medical needs in its core therapeutic areas of eye health, gastroenterology, and dermatology can lead to the development of breakthrough treatments. Successful product launches can drive revenue growth and enhance the company's competitive position. The pharmaceutical R&D spending is expected to reach $230 billion in 2026.
• Strategic Acquisitions and Partnerships: Bausch Health can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. Acquiring companies with complementary products or technologies can accelerate growth and create synergies. Partnering with other companies can provide access to new markets and distribution channels. The mergers and acquisitions in the healthcare sector are expected to remain active in the coming years.
• Focus on Over-the-Counter (OTC) Products: The OTC market offers a significant growth opportunity for Bausch Health. By expanding its OTC product line and increasing its marketing efforts, the company can tap into the growing demand for self-care products. OTC products provide a stable revenue stream and can help to offset the impact of generic competition on prescription drugs. The global OTC market is projected to reach $200 billion by 2027.
• Digital Health and Telemedicine Integration: Integrating digital health technologies and telemedicine into its business model can enhance Bausch Health's customer engagement and improve patient outcomes. Developing mobile apps, online platforms, and remote monitoring devices can provide patients with convenient access to healthcare services and information. This can lead to increased customer loyalty and revenue growth. The digital health market is expected to reach $660 billion by 2028.

What Are BHC's Competitive Advantages?

• Established brands in key therapeutic areas.
• Diverse product portfolio across pharmaceuticals, medical devices, and OTC products.
• Global presence with operations in numerous countries.
• Proprietary formulations and technologies.

What Does BHC Do?

Bausch Health Companies Inc., headquartered in Laval, Canada, has evolved from its roots as Valeant Pharmaceuticals International, Inc., rebranding in July 2018. The company develops, manufactures, and markets a broad portfolio of pharmaceutical, medical device, and over-the-counter (OTC) products. Its operations are structured into five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment provides vision care, surgical, and ophthalmic pharmaceutical products. Salix focuses on gastroenterology products within the United States. The International Rx segment serves markets in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East, offering Solta products, branded and generic pharmaceuticals, OTC products, medical devices, and Bausch + Lomb products. Ortho Dermatologics provides dermatological products in the United States and Solta medical aesthetic devices internationally. The Diversified Products segment includes pharmaceutical products in neurology and other therapeutic areas, as well as generic and dentistry products in the United States. Bausch Health's diverse product range and global presence position it as a key player in the healthcare industry, addressing a wide array of medical needs.

What Products and Services Does BHC Offer?

• Develops and manufactures pharmaceutical products.
• Markets pharmaceutical products globally.
• Produces medical devices for various therapeutic areas.
• Offers over-the-counter (OTC) products for self-care.
• Focuses on eye health, gastroenterology, and dermatology.
• Operates through five distinct business segments.

How Does BHC Make Money?

• Develops and manufactures pharmaceutical products.
• Markets and sells products through various channels, including direct sales and distributors.
• Generates revenue from prescription drugs, medical devices, and OTC products.
• Invests in research and development to create new products.

What Industry Does BHC Operate In?

Bausch Health Companies Inc. operates within the competitive pharmaceutical and medical device industry. The market is characterized by increasing demand for specialized treatments in eye health, gastroenterology, and dermatology. Key trends include the rise of generic drugs, stringent regulatory requirements, and the growing importance of emerging markets. Bausch Health competes with companies like CPRX: Catalyst Pharmaceuticals, Inc., CON: Concentra Group Holdings Parent, Inc., and BEAM: Beam Therapeutics Inc., as well as other major players in the pharmaceutical and medical device sectors. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products.

Who Are BHC's Key Customers?

• Patients seeking treatment for eye health, gastroenterological, and dermatological conditions.
• Healthcare providers, including physicians and hospitals.
• Pharmacies and retailers that sell OTC products.
• Distributors who market and sell products in various regions.

Bausch Health Companies Inc. (BHC) Valuation Context

Valued at $2.27B, BHC is classified as a mid-cap stock. Analyst price targets span from $8.00 to $16.00, with a consensus of $9.83. At the current price of $6.07, that implies approximately 62% upside potential. Relative to its peer group, BHC's quantitative score of 28/100 is below the peer average of 59/100.

BHC Revenue & Earnings Trend

In Jun 2026, BHC generated $2.85B in top-line revenue, marking a sequential increase of 13.0%. The company recorded net income of $258.0M, with diluted EPS of $0.68. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, BHC averaged $-0.74 in diluted EPS.

Company Profile

Bausch Health Companies Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Laval, CA. The company is led by CEO Thomas J. Appio. BHC has traded publicly since 1994.

Return on equity for Bausch Health Companies Inc. stands at 120.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -4.9%, showing how much profit it generates from its asset base. Its free cash flow yield is 51.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -61.7%, the inverse of the P/E and a quick read on earnings relative to price.

Bausch Health Companies Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.09 places it in the distress zone, a signal of elevated financial risk.

Bausch Health Companies Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.1% below estimates on average.

Wall Street analysts project Bausch Health Companies Inc. revenue of about $11.10B for fiscal 2026, with EPS near $4.63. The estimate reflects 4 contributing analysts.

Over the past six months, Bausch Health Companies Inc. insiders filed 20 SEC Form 4 transactions — 5 sales and 15 purchases. On net that is roughly 359K shares acquired (about $342K) — insiders putting money in tends to read as conviction.

BHC Financials

BHC Latest News

BHC Analyst Consensus

BHC MoonshotScore

Bausch Health Companies Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources